UK markets closed

Oramed Pharmaceuticals Inc. (ORMP)

NasdaqCM - NasdaqCM Real-time price. Currency in USD
Add to watchlist
2.3000-0.0300 (-1.29%)
At close: 04:00PM EDT
Currency in USD

Valuation measures4

Market cap (intra-day) 94.67M
Enterprise value -49.37M
Trailing P/E 8.96
Forward P/E N/A
PEG ratio (5-yr expected) N/A
Price/sales (ttm)141.55
Price/book (mrq)0.57
Enterprise value/revenue -25.49
Enterprise value/EBITDA 1.70

Trading information

Stock price history

Beta (5Y monthly) 1.86
52-week change 3-47.76%
S&P500 52-week change 326.36%
52-week high 35.2500
52-week low 31.6700
50-day moving average 32.5856
200-day moving average 32.5906

Share statistics

Avg vol (3-month) 3133.86k
Avg vol (10-day) 379.88k
Shares outstanding 540.63M
Implied shares outstanding 640.63M
Float 836.8M
% held by insiders 111.27%
% held by institutions 113.99%
Shares short (30 Apr 2024) 4324.61k
Short ratio (30 Apr 2024) 43.06
Short % of float (30 Apr 2024) 40.88%
Short % of shares outstanding (30 Apr 2024) 40.80%
Shares short (prior month 28 Mar 2024) 4583.94k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 21:12
Last split date 323 Jan 2013

Financial highlights

Fiscal year

Fiscal year ends 31 Dec 2023
Most-recent quarter (mrq)31 Mar 2024

Profitability

Profit margin 1,551.33%
Operating margin (ttm)-2,006.38%

Management effectiveness

Return on assets (ttm)-4.65%
Return on equity (ttm)6.48%

Income statement

Revenue (ttm)674k
Revenue per share (ttm)0.02
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -13.31M
Net income avi to common (ttm)10.46M
Diluted EPS (ttm)0.2600
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)176.59M
Total cash per share (mrq)4.35
Total debt (mrq)32.56M
Total debt/equity (mrq)19.65%
Current ratio (mrq)5.28
Book value per share (mrq)4.11

Cash flow statement

Operating cash flow (ttm)-6.22M
Levered free cash flow (ttm)-7.14M